Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. - Wikidata - wikimedia - TriplyDB

Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.

Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.

http://www.wikidata.org/entity/Q33707423

about

Acute promyelocytic leukemia with cryptic t(15;17) on isochromosome 17: a case report and review of literature Microgranular variant of acute promyelocytic leukemia with der(17) ins(17;15): A case report and review of the literature Single-nucleotide polymorphism array-based karyotyping of acute promyelocytic leukemia.Therapy-related acute promyelocytic leukemia: observations relating to APL pathogenesis and therapy.Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype.A rare case of microgranular acute promyelocytic leukemia associated with ider(17)(q10)t(15;17) in an old-age patient Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy.Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARA Acute promyelocytic leukemia: an experience on 95 greek patients treated in the all-trans-retinoic Acid era A Pediatric Acute Promyelocytic Leukemia With a Rare Karyotype of ider(17)(q10)t(15;17) and Favorable Outcome: A Case Report Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia.Current routine practice and clinico-pathological characteristics associated with acute promyelocytic leukemia in Korea.Acute Promyelocytic Leukemia with i(17)(q10).Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients.Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.Characteristics features and factors influencing early death in Acute promyelocytic leukemia; Experience from United Arab Emirates (UAE).ATRA and anthracycline-based chemotherapy in the treatment of childhood acute promyelocytic leukemia (APL): A 10-year experience in Tunisia.APL-The Age-Old Harlequin: Do We See it All?Impact of additional chromosomal abnormalities in patients with acute promyelocytic leukemia: 10-year results of the Japan Adult Leukemia Study Group APL97 study.FISH-negative, cytogenetically cryptic acute promyelocytic leukemia.Long-term survey of outcome in acute promyelocytic leukemia: a single center experience in 340 patients.Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631.Coexistence of PML-RARα and BCR-ABL in acute promyelocytic leukemia.Acute promyelocytic leukaemia with a PML-RARA insertional translocation and a chromosome 21 abnormality in XYY syndrome: case report.Prognostic significance of additional cytogenetic abnormalities and FLT3 mutations in acute promyelocytic leukemia.Acute myeloid leukemia

P2860

Q28073281-B664402B-8757-46E4-996E-B1840090C080 Q33428004-976107E7-E7FF-4423-94E9-717873ED1600 Q33800102-3ED8A7C5-8D48-48D9-8D9E-79A621BE275E Q34227027-7977F298-9C3D-4392-9D87-1EB5D60554CF Q34754867-C73F6922-18AB-4C75-95BA-D479CAB6AABB Q35048056-6B1660D8-851E-432F-A3A7-0C75EF80532F Q35265901-2FD60A63-A049-47C5-8CC2-9851DAF067FE Q35596919-A65D5DD2-890D-49B3-AEB8-14E2818B6EDA Q35640734-EA385AC7-C3B2-48A8-B378-52BD0FD1A755 Q36195613-5C9AF527-7E87-4AAE-A6DB-AAF7C4B56711 Q36220730-CCA1B2AC-2D3E-4C56-A3B0-D7EE1E83236A Q36761829-AB26F683-2FE3-4E77-9F52-E8AFA386E3B1 Q37521156-4AA864EF-FDE9-4FDA-8493-CF6AA2C549AF Q38752325-6617587B-DAFE-4F6A-A7F6-5C89F020A9A4 Q38891536-3BD9EBEE-5BDB-4B15-92EE-198AE62D7B30 Q38907861-D12721B1-721B-46CF-B1C6-512A9EEF228E Q39103005-25632E4D-FEA0-4536-90D4-DCE139D55458 Q41815626-392171C1-87C6-4C42-A5FE-25A4327E1114 Q42558477-873BD0D7-1145-447B-A917-5B4DED9CD343 Q43170183-0E110400-04B4-439C-8EEB-83D599508F71 Q44242245-0091D71D-2EF0-4DCB-ABE3-51E7D96BFF8F Q46165728-0A98AB9A-6380-47A9-A7BC-B8F618EF75D9 Q50967775-A3E92626-24A4-41FD-8E39-45D47E2E97CA Q51053584-E2AC833F-A91B-4DD5-9053-B3AE0233771B Q54392009-16B6C8F0-6130-4416-A82E-8BDF87AEC0AE Q58481761-B8AA46FD-298E-404D-B002-7CF50EB40928

P2860

Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.

http://www.wikidata.org/entity/Q33707423

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Additional chromosome abnormal ...... etinoic acid and chemotherapy.

@ast

Additional chromosome abnormal ...... etinoic acid and chemotherapy.

@en

type

label

Additional chromosome abnormal ...... etinoic acid and chemotherapy.

@ast

Additional chromosome abnormal ...... etinoic acid and chemotherapy.

@en

prefLabel

Additional chromosome abnormal ...... etinoic acid and chemotherapy.

@ast

Additional chromosome abnormal ...... etinoic acid and chemotherapy.

@en

P1433

Q33707423-A54E8A90-27D8-40D2-9DE1-C97C6814BF9B

P1476

Q33707423-31380255-08B9-48A2-A310-0F137C4C0D46

P2093

Q33707423-16DAC27A-05D2-45D8-B7B7-542AC5A31606

Q33707423-1AB0EB3E-E6FF-4880-95BF-327EE1A7E2B4

Q33707423-31FA0CE5-5BA0-45E7-A088-D6DF6D4D08DA

Q33707423-33932837-EBCF-4A16-8017-D01096896EB7

Q33707423-517472B5-2ABA-4F44-9A78-BCA7DA9EECA4

Q33707423-63CC1D37-C2F0-4114-9DBE-7C0813D9F45B

Q33707423-654BBCD2-C7EF-4A4C-A7D9-B2722C6A2422

Q33707423-6558F971-88DE-426B-A22A-078117BD6491

Q33707423-6E884861-A366-4A1C-9525-6F28E1190112

Q33707423-753B3EF0-836D-41AB-BE5F-2AC9D88D371F

P2860

Q33707423-02266387-7327-48B1-967D-EACA45061A48

Q33707423-15DE1DAB-400B-4A18-ACB0-5575294C6F2B

Q33707423-30717877-DD7F-489F-981C-5FE14815B2A2

Q33707423-4043855B-923E-4343-90E0-8EE6310E9C15

Q33707423-5330F88F-A662-46EB-8ECE-5075D84BCE7A

Q33707423-54406C88-DDAD-4544-86BE-E374BF24F493

Q33707423-648F33B0-15DF-4353-8758-0A51D8FBFF31

Q33707423-7728CBC1-28D4-4F70-B8D6-03A5CB63A34C

Q33707423-91583C11-3431-47E1-8776-C6290FBBB4BD

Q33707423-A5AAAF31-0832-44C7-86DC-2AD6C152565A

P304

Q33707423-5984E46A-ADD1-4319-85B7-92F4D83A6BD7

P31

Q33707423-7493902F-34D7-4F9E-A761-D2C861A842EE

P356

Q33707423-089B91CC-7D0B-4D58-934A-2C82144EB28D

P433

Q33707423-8C24262E-0C82-4E8D-B327-E4A2F740830C

P478

Q33707423-514215BD-E69C-4D9A-B2A6-9BA023F57FB9

P50

Q33707423-009E6E87-B299-4643-9D09-CBAEF847B965

Q33707423-3D6F4B67-C7D5-4E56-AA9D-053E31260F8D

Q33707423-534687D1-B1B5-429C-8055-B9C62D94DA73

Q33707423-A7836E9A-1B1D-4D88-B20F-3E580B02BDB4

Q33707423-BE3526DF-BB41-48DB-9BD8-6189D66C20C5

Q33707423-F0134174-3668-4848-A2EE-F43FA427EE62

P577

Q33707423-0F0BBCD2-A281-48BE-842D-94384390BC5F

P5875

Q33707423-BECC625E-CC39-4B4C-B822-67947ED31A82

P698

Q33707423-C13A9341-CDA1-441E-8175-D8B7086BAB7F

P921

Q33707423-49432D24-BDF3-40D2-8853-4870E6693F05

Q33707423-889E83C0-4FC9-4D6B-BFAB-E59A2FBBD96F

P932

Q33707423-F8EC1C37-CAA9-4162-92E7-6A1493814ECA

P356

HAEMATOL.2009.013243

P1433

P1476

Additional chromosome abnormal ...... retinoic acid and chemotherapy

@en

P2093

Anna Aventín

http://www.w3.org/2001/XMLSchema#string

Bob Lowenberg

http://www.w3.org/2001/XMLSchema#string

Chelo Rayón

http://www.w3.org/2001/XMLSchema#string

Concha Rivas

http://www.w3.org/2001/XMLSchema#string

Edo Vellenga

http://www.w3.org/2001/XMLSchema#string

Elena Amutio

http://www.w3.org/2001/XMLSchema#string

Elisa Luño

http://www.w3.org/2001/XMLSchema#string

Gustavo Milone

http://www.w3.org/2001/XMLSchema#string

Javier Sánchez

http://www.w3.org/2001/XMLSchema#string

José Cervera

http://www.w3.org/2001/XMLSchema#string

P2860

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study

Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties

Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Groupe Français de Cytogénétique Hématologique, Groupe de Français d'Hematologie Cellulaire, UK Cancer Cytogenetics Group and

Evaluation of survival data and two new rank order statistics arising in its consideration.

A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group.

Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group.

Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations

Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin.

P304

424-431

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3324/HAEMATOL.2009.013243

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

95

http://www.w3.org/2001/XMLSchema#string

P50

Javier de la Serna

Jose-Angel Hernandez-Rivas

P577

2009-11-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38080401

http://www.w3.org/2001/XMLSchema#string

P698

19903674

http://www.w3.org/2001/XMLSchema#string

P921

P932

2833072

http://www.w3.org/2001/XMLSchema#string